Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Edesa Biotech, Inc. (EDSA)

Edesa Biotech grants Kyorin Japan rights to paridiprubart for $12 million upfront

Positive Impact 4 of 5 product/contract

Edesa Biotech entered a Collaboration and License Agreement dated November 8, 2026, giving Kyorin Pharmaceutical exclusive rights to develop and sell paridiprubart for ARDS in Japan, while Edesa keeps rights elsewhere, including the United States, Europe and Canada. The deal provides a $12 million upfront payment, milestone payments and royalties, and Edesa also gave notice that it is terminating its at-the-market share sales agreement with H.C. Wainwright, effective November 16, 2026.

Key points

  • Kyorin pays a one-time, non-refundable upfront payment of $12 million
  • Development and regulatory milestones of up to $55 million, plus sales-based milestones of up to ¥12.0 billion
  • Kyorin pays tiered, low double-digit royalties on net sales in Japan
  • ATM agreement with H.C. Wainwright terminated effective November 16, 2026, with no termination penalties

The filing

CompanyEdesa Biotech, Inc. (EDSA)
Form8-K, current report
Filed with the SECNov 9, 2026, 6:05 AM ET
Accession number0001171843-26-007242

Items reported: 1.01 Material Definitive Agreement1.02 Termination of Material Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.